SLX 3065
Alternative Names: SLX-3065Latest Information Update: 19 Jul 2024
At a glance
- Originator Biolexis Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin-dependent kinase 9 degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Prostate cancer
Most Recent Events
- 05 Apr 2024 Preclinical trials in Prostate cancer in USA (unspecified route), before April 2024
- 05 Apr 2024 Biolexis Therapeutics plans to IND-enabling studies
- 05 Apr 2024 Pharmacodynamics data from a preclinical study in Prostate cancers presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)